![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TFDP1 |
Gene summary for TFDP1 |
![]() |
Gene information | Species | Human | Gene symbol | TFDP1 | Gene ID | 7027 |
Gene name | transcription factor Dp-1 | |
Gene Alias | DILC | |
Cytomap | 13q34 | |
Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | A0A024RDY4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7027 | TFDP1 | LZE8T | Human | Esophagus | ESCC | 6.63e-03 | 1.35e-01 | 0.067 |
7027 | TFDP1 | LZE24T | Human | Esophagus | ESCC | 2.26e-02 | 2.38e-02 | 0.0596 |
7027 | TFDP1 | P2T-E | Human | Esophagus | ESCC | 1.34e-29 | 7.15e-01 | 0.1177 |
7027 | TFDP1 | P4T-E | Human | Esophagus | ESCC | 6.35e-29 | 9.09e-01 | 0.1323 |
7027 | TFDP1 | P5T-E | Human | Esophagus | ESCC | 3.39e-26 | 5.33e-01 | 0.1327 |
7027 | TFDP1 | P8T-E | Human | Esophagus | ESCC | 5.43e-27 | 5.61e-01 | 0.0889 |
7027 | TFDP1 | P9T-E | Human | Esophagus | ESCC | 4.59e-05 | 1.59e-01 | 0.1131 |
7027 | TFDP1 | P10T-E | Human | Esophagus | ESCC | 2.01e-23 | 5.35e-01 | 0.116 |
7027 | TFDP1 | P11T-E | Human | Esophagus | ESCC | 7.15e-08 | 6.76e-01 | 0.1426 |
7027 | TFDP1 | P12T-E | Human | Esophagus | ESCC | 8.80e-22 | 4.38e-01 | 0.1122 |
7027 | TFDP1 | P15T-E | Human | Esophagus | ESCC | 3.02e-12 | 2.49e-01 | 0.1149 |
7027 | TFDP1 | P16T-E | Human | Esophagus | ESCC | 2.59e-26 | 6.11e-01 | 0.1153 |
7027 | TFDP1 | P17T-E | Human | Esophagus | ESCC | 7.25e-09 | 3.35e-01 | 0.1278 |
7027 | TFDP1 | P19T-E | Human | Esophagus | ESCC | 7.53e-05 | 5.84e-01 | 0.1662 |
7027 | TFDP1 | P20T-E | Human | Esophagus | ESCC | 1.10e-13 | 3.12e-01 | 0.1124 |
7027 | TFDP1 | P21T-E | Human | Esophagus | ESCC | 1.56e-27 | 6.01e-01 | 0.1617 |
7027 | TFDP1 | P22T-E | Human | Esophagus | ESCC | 2.03e-10 | 2.32e-01 | 0.1236 |
7027 | TFDP1 | P23T-E | Human | Esophagus | ESCC | 3.24e-11 | 2.89e-01 | 0.108 |
7027 | TFDP1 | P24T-E | Human | Esophagus | ESCC | 2.03e-15 | 3.28e-01 | 0.1287 |
7027 | TFDP1 | P26T-E | Human | Esophagus | ESCC | 8.84e-11 | 2.67e-01 | 0.1276 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
GO:007189716 | Esophagus | ESCC | DNA biosynthetic process | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:2000278110 | Esophagus | ESCC | regulation of DNA biosynthetic process | 81/8552 | 106/18723 | 9.81e-11 | 2.96e-09 | 81 |
GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
GO:004593116 | Esophagus | ESCC | positive regulation of mitotic cell cycle | 83/8552 | 121/18723 | 2.78e-07 | 4.08e-06 | 83 |
GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
GO:000008214 | Esophagus | ESCC | G1/S transition of mitotic cell cycle | 134/8552 | 214/18723 | 4.04e-07 | 5.55e-06 | 134 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:004484314 | Esophagus | ESCC | cell cycle G1/S phase transition | 148/8552 | 241/18723 | 5.68e-07 | 7.48e-06 | 148 |
GO:19019896 | Esophagus | ESCC | positive regulation of cell cycle phase transition | 77/8552 | 115/18723 | 3.20e-06 | 3.58e-05 | 77 |
GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
GO:00900689 | Esophagus | ESCC | positive regulation of cell cycle process | 142/8552 | 236/18723 | 4.79e-06 | 5.08e-05 | 142 |
GO:19019925 | Esophagus | ESCC | positive regulation of mitotic cell cycle phase transition | 62/8552 | 93/18723 | 3.47e-05 | 2.83e-04 | 62 |
GO:00432761 | Esophagus | ESCC | anoikis | 26/8552 | 34/18723 | 2.53e-04 | 1.55e-03 | 26 |
GO:200004513 | Esophagus | ESCC | regulation of G1/S transition of mitotic cell cycle | 82/8552 | 142/18723 | 2.49e-03 | 1.08e-02 | 82 |
GO:190280613 | Esophagus | ESCC | regulation of cell cycle G1/S phase transition | 95/8552 | 168/18723 | 2.91e-03 | 1.22e-02 | 95 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0435014 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa043506 | Oral cavity | OSCC | TGF-beta signaling pathway | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0435013 | Oral cavity | OSCC | TGF-beta signaling pathway | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa0411022 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
hsa0411032 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TFDP1 | SNV | Missense_Mutation | c.500N>A | p.Arg167Gln | p.R167Q | Q14186 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TFDP1 | SNV | Missense_Mutation | c.764C>T | p.Ser255Leu | p.S255L | Q14186 | protein_coding | deleterious(0.02) | benign(0.023) | TCGA-EY-A5W2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TFDP1 | SNV | Missense_Mutation | rs571820111 | c.790N>A | p.Val264Ile | p.V264I | Q14186 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TFDP1 | SNV | Missense_Mutation | novel | c.994N>T | p.Pro332Ser | p.P332S | Q14186 | protein_coding | tolerated(0.22) | probably_damaging(0.998) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TFDP1 | SNV | Missense_Mutation | novel | c.346N>A | p.Leu116Ile | p.L116I | Q14186 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
TFDP1 | SNV | Missense_Mutation | novel | c.1093N>G | p.Thr365Ala | p.T365A | Q14186 | protein_coding | tolerated(0.31) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
TFDP1 | SNV | Missense_Mutation | c.110N>T | p.Ser37Phe | p.S37F | Q14186 | protein_coding | tolerated(0.07) | benign(0.226) | TCGA-FV-A496-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TFDP1 | SNV | Missense_Mutation | c.338N>A | p.Gly113Asp | p.G113D | Q14186 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-44-2657-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TFDP1 | SNV | Missense_Mutation | novel | c.915N>T | p.Met305Ile | p.M305I | Q14186 | protein_coding | deleterious(0.01) | benign(0.329) | TCGA-50-5932-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TFDP1 | SNV | Missense_Mutation | novel | c.916N>T | p.Ala306Ser | p.A306S | Q14186 | protein_coding | tolerated(0.54) | possibly_damaging(0.741) | TCGA-50-5932-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |